Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06686771 · ClinicalTrials.gov registry record · Phase 3
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Canadian Cancer Trials Group.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 320
- Enrollment target
- 20
- Study locations
NCT06686771 is a Phase 3 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Canadian Cancer Trials Group. The registered enrollment target is 320 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT06686771, a Phase 3 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Canadian Cancer Trials Group.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 320 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approach is better or worse than the usual approach for lung cancer. The usual approach is defined as the care most people get for non-small cell lung cancer.
Conditions Studied
Interventions
- RADIATION SBRT
- OTHER First or second-line standard of care therapy
Study Locations (20)
Illinois
- Alton Memorial Hospital - Alton
- Northwestern University - Chicago
- Decatur Memorial Hospital - Decatur
- Northwestern Medicine Cancer Center Kishwaukee - DeKalb
- Crossroads Cancer Center - Effingham
- Northwestern Medicine Cancer Center Delnor - Geneva
- Northwestern Medicine Glenview Outpatient Center - Glenview
- Northwestern Medicine Grayslake Outpatient Center - Grayslake
- Northwestern Medicine Lake Forest Hospital - Lake Forest
- HSHS Saint Elizabeth's Hospital - O'Fallon
- Northwestern Medicine Oak Brook - Oak Brook
- Northwestern Medicine Orland Park - Orland Park
- Memorial Hospital East - Shiloh
Idaho
- Saint Luke's Cancer Institute - Boise - Boise
- Saint Luke's Cancer Institute - Fruitland - Fruitland
- Saint Luke's Cancer Institute - Meridian - Meridian
- Saint Luke's Cancer Institute - Nampa - Nampa
California
- City of Hope Comprehensive Cancer Center - Duarte
- City of Hope at Irvine Lennar - Irvine
Colorado
- Saint Mary's Hospital and Regional Medical Center - Grand Junction
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2025-12-16 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06686771
The ClinicalTrials.gov registry entry for NCT06686771 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (51% lower). The listed sponsor is Canadian Cancer Trials Group, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which SBRT is the first listed.
NCT06686771 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Illinois, Idaho, California.
Frequently Asked Questions
What is clinical trial NCT06686771 about?
NCT06686771 is a clinical study titled "Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer". This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approach is better or worse than the usual approach for lung cance...
What is the current status of trial NCT06686771?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 320 participants. The study started on 2025-12-16. Estimated completion is 2030-12-31.
What conditions does trial NCT06686771 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT06686771?
The interventions under investigation include: SBRT (RADIATION), First or second-line standard of care therapy (OTHER).
Who is sponsoring clinical trial NCT06686771?
This trial is sponsored by Canadian Cancer Trials Group, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06686771 being conducted?
This trial has 20 study locations across California, Colorado, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.